Related Experiment Videos
Danazol induced pancreatitis and hepatitis.
X Chevalier1, H Awada, A Baetz
1Clinique de Rhumatologie, Hôpital Cochin, Paris.
Clinical Rheumatology
|June 1, 1990
Summary
Danazol, used for systemic lupus erythematosus, can cause liver and pancreatic issues. This case highlights potential danazol-induced pancreatitis and hepatitis in patients.
Area of Science:
- Endocrinology
- Hepatology
- Gastroenterology
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease managed with various therapies.
- Danazol, a C17 alkylated anabolic steroid, has been explored as a potential hormonomodulator for SLE.
- Hormonal therapies are investigated for their immunomodulatory effects in autoimmune conditions.
Observation:
- A case study involving a patient treated with danazol for SLE.
- The patient was administered a daily dosage of 400 mg of danazol.
- Clinical observation of adverse events during danazol therapy.
Findings:
- Danazol administration was associated with the development of mild pancreatitis.
- Hepatitis was also observed in the patient concurrently with pancreatitis.
- Both pancreatitis and hepatitis were determined to be induced by danazol.
Implications:
- Danazol's use in SLE management may be limited by potential hepatotoxicity and pancreatic side effects.
- Clinicians should monitor for gastrointestinal and hepatic adverse events in patients receiving danazol.
- Further research is warranted to assess the risk-benefit profile of danazol in autoimmune diseases.